Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biovea Probiotic Complex is a multi-strain dietary supplement containing four probiotic bacterial strains: *Lactobacillus acidophilus*, *Bifidobacterium lactis*, *Lactobacillus salivarius*, and *Bifidobacterium bifidum*. It is formulated to support gastrointestinal health and immune function by replenishing beneficial microflora. In a Phase 3 clinical trial conducted by October 6 University, this specific probiotic blend was evaluated as a systemic adjunctive therapy alongside topical clobetasol propionate for the treatment of oral lichen planus (OLP). The rationale for its use in OLP involves the modulation of the oral and systemic microbiome to reduce inflammatory responses and mitigate secondary complications such as oral candidiasis, which is frequently associated with the use of potent topical corticosteroids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biovea Probiotic Complex.